Preparing for Market: Reimbursement Strategies for Cell and Gene Therapies

Posted 08 September 2017

placeholder+image In this interview with Regulatory Focus, Ted Slocomb and Michael Werner, two leaders from the Alliance for Regenerative Medicine (ARM), provide insight into future challenges and opportunities for ensuring market access and value-based reimbursement for gene and cell therapies.

Share this article:

Categories: Biologics and biotechnology, Human cell and tissue, Reimbursement, Features, US, FDA

Tags: Regenerative Medicine, ARM, Michael Werner, Ted Slocomb

Regulatory Exchange: Latest Updates From the Community